Convergence Investment Partners, LLC Gilead Sciences, Inc. Transaction History

Convergence Investment Partners, LLC

$365 Million
Q3 2024

A detailed history of Convergence Investment Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Convergence Investment Partners, LLC holds 59,117 shares of GILD stock, worth $5.4 Million. This represents 1.36% of its overall portfolio holdings.

Number of Shares

59,117

Previous 50,885 16.18%

Holding current value

$5.4 Million

Previous $3.49 Million 41.94%

% of portfolio

1.36%

Previous 1.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$66.59 - $83.99 $548,168 - $691,405	8,232 Added 16.18%	59,117 $4.96 Million
Q2 2024 Aug 01, 2024	SELL	$63.15 - $72.88 $12,187 - $14,065	-193 Reduced 0.38%	50,885 $3.49 Million
Q1 2024 May 03, 2024	BUY	$71.58 - $87.29 $385,744 - $470,405	5,389 Added 11.79%	51,078 $3.74 Million
Q4 2023 Feb 05, 2024	SELL	$73.27 - $83.09 $256,078 - $290,399	-3,495 Reduced 7.11%	45,689 $3.7 Million
Q3 2023 Nov 02, 2023	SELL	$73.94 - $80.67 $13,752 - $15,004	-186 Reduced 0.38%	49,184 $3.69 Million
Q2 2023 Jul 26, 2023	SELL	$76.01 - $86.7 $116,067 - $132,390	-1,527 Reduced 3.0%	49,370 $3.81 Million
Q1 2023 May 09, 2023	SELL	$77.31 - $88.08 $3,556 - $4,051	-46 Reduced 0.09%	50,897 $4.22 Million
Q4 2022 Feb 03, 2023	BUY	$62.32 - $89.47 $53,408 - $76,675	857 Added 1.71%	50,943 $4.37 Million
Q3 2022 Nov 08, 2022	BUY	$59.54 - $68.01 $1.1 Million - $1.26 Million	18,540 Added 58.77%	50,086 $3.09 Million
Q2 2022 Aug 05, 2022	SELL	$57.72 - $65.01 $173,564 - $195,485	-3,007 Reduced 8.7%	31,546 $1.95 Million
Q1 2022 Apr 26, 2022	BUY	$57.92 - $72.58 $22,472 - $28,161	388 Added 1.14%	34,553 $2.05 Million
Q4 2021 Jan 25, 2022	BUY	$64.88 - $73.64 $60,597 - $68,779	934 Added 2.81%	34,165 $2.48 Million
Q3 2021 Oct 25, 2021	BUY	$67.69 - $73.03 $364,036 - $392,755	5,378 Added 19.31%	33,231 $2.32 Million
Q2 2021 Jul 19, 2021	SELL	$63.47 - $69.35 $253,308 - $276,775	-3,991 Reduced 12.53%	27,853 $1.92 Million
Q1 2021 Apr 30, 2021	BUY	$60.0 - $68.46 $4,560 - $5,202	76 Added 0.24%	31,844 $2.06 Million
Q4 2020 Feb 05, 2021	SELL	$56.65 - $64.55 $1.88 Million - $2.14 Million	-33,152 Reduced 51.07%	31,768 $1.85 Million
Q3 2020 Oct 28, 2020	SELL	$62.1 - $78.08 $155,063 - $194,965	-2,497 Reduced 3.7%	64,920 $4.1 Million
Q2 2020 Jul 30, 2020	BUY	$72.34 - $84.0 $271,275 - $315,000	3,750 Added 5.89%	67,417 $5.19 Million
Q1 2020 Apr 23, 2020	BUY	$62.63 - $80.22 $89,185 - $114,233	1,424 Added 2.29%	63,667 $4.76 Million
Q4 2019 Jan 22, 2020	SELL	$61.62 - $67.78 $75,053 - $82,556	-1,218 Reduced 1.92%	62,243 $4.05 Million
Q3 2019 Oct 22, 2019	BUY	$62.51 - $69.0 $2 Million - $2.2 Million	31,953 Added 101.41%	63,461 $4.02 Million
Q2 2019 Jul 23, 2019	BUY	$61.87 - $69.38 $12,188 - $13,667	197 Added 0.63%	31,508 $2.13 Million
Q1 2019 May 01, 2019	BUY	$62.53 - $70.05 $8,816 - $9,877	141 Added 0.45%	31,311 $2.04 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $294,829 - $384,730	4,870 Added 18.52%	31,170 $1.95 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $525,618 - $581,956	7,374 Added 38.96%	26,300 $2.03 Million
Q2 2018 Aug 07, 2018	SELL	$64.88 - $75.68 $796,726 - $929,350	-12,280 Reduced 39.35%	18,926 $1.34 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $4.58 Million - $5.58 Million	-62,852 Reduced 66.82%	31,206 $2.35 Million
Q4 2017 Jan 16, 2018	BUY	$71.15 - $83.52 $1,849 - $2,171	26 Added 0.03%	94,058 $6.74 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $6.78 Million - $8.04 Million	94,032	94,032 $7.62 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.

Account

Convergence Investment Partners, LLC Gilead Sciences, Inc. Transaction History